Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

NCT03018028 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

243

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: Semaglutide
DRUG: Placebo
DRUG: Liraglutide

Sponsor

Novo Nordisk A/S